Stock to watch on  11 April 2025

By 5paisa

TCS reported a 1.6% drop in Q4 FY25 net profit to ₹12,224 crore, even as revenue rose to ₹64,479 crore from ₹61,237 crore YoY.

CuraTeQ Biologics, a unit of Aurobindo Pharma, completed Phase 1 trials of its denosumab biosimilar, targeting bone resorption treatment.

Bharti Hexacom paused its existing infra sale proposal and will reassess the deal with Indus Towers after guidance from TCIL.

BHEL signed an MoU with Italy’s Nuovo Pignone to jointly take on compressor revamp projects in India’s fertilizer sector.

Infosys extended its strategic partnership with AIB to provide agile, AI-driven application development and maintenance services.

Investment/Trading in securities market is subject to market risk, past performance is not a guarantee of future performance. The risk of loss in trading and investment in Securities markets including Equities and Derivatives can be substantial.

Disclaimer